Compare COSM & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COSM | RNAZ |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.8M | 27.9M |
| IPO Year | 2009 | 2021 |
| Metric | COSM | RNAZ |
|---|---|---|
| Price | $0.30 | $1.64 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | ★ $2.95 | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 29.5K |
| Earning Date | 11-16-2026 | 08-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.15 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $65,271,815.00 | N/A |
| Revenue This Year | $30.85 | N/A |
| Revenue Next Year | $51.74 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.93 | N/A |
| 52 Week Low | $0.16 | $1.52 |
| 52 Week High | $0.83 | $12.60 |
| Indicator | COSM | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 50.09 | 42.81 |
| Support Level | $0.29 | $1.57 |
| Resistance Level | $0.40 | $1.95 |
| Average True Range (ATR) | 0.04 | 0.16 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 46.31 | 21.95 |
Cosmos Health Inc is a diversified, vertically integrated healthcare group, owner of proprietary pharmaceutical and nutraceutical brands, generics, manufacturer and distributor of healthcare products, engaged in research & development of medicines and repurposing drugs as well as operator of a telehealth platform. The company has developed its own proprietary branded nutraceutical products, named 'Sky Premium Life' and 'Mediterranation'. Its product portfolio includes generics and over-the-counter pharmaceutical products, medicines, as well as nutraceuticals and biocides. The company's Reportable segments are Wholesale, Pharma manufacturing, and Nutraceutical and pharmaceuticals, with the majority of revenue generated from the Wholesale segment.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.